To examine the roles of MET, EGFR, HER2, HER3, and RET in lung cancer cells with MET amplification, we first investigated the effects of PHA-665752, gefitinib, lapatinib, and vandetanib on cell proliferation and survival. The gene discussed is ERBB3; the disease is lung carcinoma.